To further elucidate whether STARD4 regulates the progression and lenvatinib resistance of HCC via EGFR activation, we investigated the impact of EGFR inhibitor erlotinib on the tumor-promoting effect of STARD4 in HCC cells. Here, EGFR is linked to hepatocellular carcinoma.